Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators.Evaluation of 7E3 in Preventing Ischemic Complications
AM Lincoff,
RM Califf,
KM Anderson,
HF Weisman,
FV Aguirre,
NS Kleiman,
RA Harrington,
and
EJ Topol
Department of Cardiology, Cleveland Clinic Foundation, Ohio 44195, USA.
OBJECTIVES: We sought to evaluate whether patients with unstable angina undergoing coronary intervention derive particular clinical benefit from potent platelet inhibition. BACKGROUND: Plaque rupture and platelet aggregation are pathogenetic processes common to unstable angina and ischemic complications of percutaneous coronary intervention. METHODS: Of the 2,099 patients undergoing a coronary intervention in the Evaluation of 7E3 in Preventing Ischemic Complications (EPIC) trial, 489 were enrolled with the diagnosis of unstable angina and randomized to receive placebo, an abciximab (c7E3) bolus immediately before the intervention or an abciximab bolus followed by a 12-h infusion. The primary end point was a composite of death, myocardial infarction (MI) or urgent repeat revascularization within 30 days of randomization. The occurrence of death, MI or any revascularization within 6 months was also assessed. RESULTS: Compared with placebo, the bolus and infusion of abciximab resulted in a 62% reduction in the rate of the primary end point (12.8% vs. 4.8%, p = 0.012) among patients with unstable angina, due primarily to a reduction in the incidences of death (3.2% vs. 1.2%, p = 0.164) and MI (9% vs. 1.8%, p = 0.004). By 6 months, cumulative death and MI were further reduced by abciximab (6.6% vs. 1.8%, p = 0.018 and 11.1% vs. 2.4%, p = 0.002, respectively). The magnitude of the risk reduction with abciximab was greater among the patients with unstable angina than among other patients in the EPIC trial without unstable angina for the end points of death (interaction: p = 0.008 at 30 days, p = 0.002 at 6 months) and MI (interaction: p = 0.004 at 30 days, p = 0.003 at 6 months). CONCLUSIONS: The syndrome of unstable angina identifies patients who will experience particularly marked reductions in the risk of death and MI with abciximab during coronary intervention.
This article has been cited by other articles:
|
|
|
|
 
R. A. G. Patel and C. J. White
Survival Benefit With Concomitant Oral Platelet Therapy After Coronary Angiography and Before Ad Hoc Percutaneous Coronary Intervention
Mayo Clin. Proc.,
September 1, 2008;
83(9):
978 - 979.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Anderson, C. D. Adams, E. M. Antman, C. R. Bridges, R. M. Califf, D. E. Casey Jr, W. E. Chavey II, F. M. Fesmire, J. S. Hochman, T. N. Levin, et al.
ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine
J. Am. Coll. Cardiol.,
August 14, 2007;
50(7):
e1 - e157.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Anderson, C. D. Adams, E. M. Antman, C. R. Bridges, R. M. Califf, D. E. Casey Jr, W. E. Chavey II, F. M. Fesmire, J. S. Hochman, T. N. Levin, et al.
ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine
J. Am. Coll. Cardiol.,
August 14, 2007;
50(7):
652 - 726.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Authors/Task Force Members, J.-P. Bassand, C. W. Hamm, D. Ardissino, E. Boersma, A. Budaj, F. Fernandez-Aviles, K. A.A. Fox, D. Hasdai, E. M. Ohman, et al.
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology
Eur. Heart J.,
July 1, 2007;
28(13):
1598 - 1660.
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. L. Miller, K. N. Garratt, M. F. Burritt, R. J. Lennon, G. S. Reeder, and A. S. Jaffe
Baseline troponin level: key to understanding the importance of post-PCI troponin elevations
Eur. Heart J.,
May 1, 2006;
27(9):
1061 - 1069.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W.H. W. Tang and A. M. Lincoff
Diabetes, Coronary Intervention, and Platelet Glycoprotein IIb/IIIa Blockade: The Triad Revisited
Circulation,
December 14, 2004;
110(24):
3618 - 3620.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Lincoff, N. S. Kleiman, D. J. Kereiakes, F. Feit, J. A. Bittl, J. D. Jackman, I. J. Sarembock, D. J. Cohen, D. Spriggs, R. Ebrahimi, et al.
Long-term Efficacy of Bivalirudin and Provisional Glycoprotein IIb/IIIa Blockade vs Heparin and Planned Glycoprotein IIb/IIIa Blockade During Percutaneous Coronary Revascularization: REPLACE-2 Randomized Trial
JAMA,
August 11, 2004;
292(6):
696 - 703.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. L. Miller, K. N. Garratt, M. F. Burritt, G. S. Reeder, and A. S. Jaffe
Timing of Peak Troponin T and Creatine Kinase-MB Elevations After Percutaneous Coronary Intervention
Chest,
January 1, 2004;
125(1):
275 - 280.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Steiner, D. Seidinger, K. Huber, C. Kaun, E. Minar, and C. W. Kopp
Effect of Glycoprotein IIb/IIIa Antagonist Abciximab on Monocyte-Platelet Aggregates and Tissue Factor Expression
Arterioscler Thromb Vasc Biol,
September 1, 2003;
23(9):
1697 - 1702.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. E. Boden
"Routine invasive" versus "selective invasive" approaches to non-ST-segment elevation acute coronary syndromes management in the post-stent/platelet inhibition era
J. Am. Coll. Cardiol.,
February 19, 2003;
41(4_Suppl_S):
113S - 122S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. K. Yarlagadda and W. E. Boden
Cardioprotective effects of an early invasive strategy for non-ST-segment elevationacute coronary syndromes: Are we all becoming "interventional" cardiologists?
J. Am. Coll. Cardiol.,
December 4, 2002;
40(11):
1915 - 1918.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. E. Bertrand, M. L. Simoons, K. A.A. Fox, L. C. Wallentin, C. W. Hamm, E. McFadden, P. J. De Feyter, G. Specchia, and W. Ruzyllo
Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
Eur. Heart J.,
December 1, 2002;
23(23):
1809 - 1840.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. R. Cusack, M. S. Marber, P. D. Lambiase, C. A. Bucknall, and S. R. Redwood
Systemic inflammation in unstable angina is the result of myocardial necrosis
J. Am. Coll. Cardiol.,
June 19, 2002;
39(12):
1917 - 1923.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P.J. de Feyter, P.W. Serruys, F. Unger, R. Beyar, V. de Valk, S. Milo, R. Simon, D. Regensburger, P.A. Crean, E. McGovern, et al.
Bypass Surgery Versus Stenting for the Treatment of Multivessel Disease in Patients With Unstable Angina Compared With Stable Angina
Circulation,
May 21, 2002;
105(20):
2367 - 2372.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S Constantinides, T S N Lo, M Been, and M F Shiu
Early experience with a helical coronary thrombectomy device in patients with acute coronary thrombosis.
Heart,
May 1, 2002;
87(5):
455 - 460.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. E. Buller and R. G. Carere
New advances in the management of acute coronary syndromes: 3. The role of catheter-based procedures
Can. Med. Assoc. J.,
January 1, 2002;
166(1):
51 - 61.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Fintel
From bench to bedside: GP IIb-IIIa inhibitors
Neurology,
September 1, 2001;
57(90002):
S12 - 19.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
A. M. Lincoff, D. J. Kereiakes, M. A. Mascelli, L. I. Deckelbaum, E. S. Barnathan, K. K. Patel, B. Frederick, M. T. Nakada, and E. J. Topol
Abciximab Suppresses the Rise in Levels of Circulating Inflammatory Markers After Percutaneous Coronary Revascularization
Circulation,
July 10, 2001;
104(2):
163 - 167.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. M. Anderson, R. M. Califf, G. W. Stone, F.-J. Neumann, G. Montalescot, D. P. Miller, J. J. Ferguson III, J. T. Willerson, H. F. Weisman, and E. J. Topol
Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention
J. Am. Coll. Cardiol.,
June 15, 2001;
37(8):
2059 - 2065.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.W. Hamm
GP IIb/IIIa receptor antagonists in unstable angina: troponin level-based patient selection
Eur. Heart J. Suppl.,
May 1, 2001;
3(suppl_A):
A14 - A20.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. J. Popma, E. M. Ohman, J. Weitz, A. M. Lincoff, R. A. Harrington, and P. Berger
Antithrombotic Therapy in Patients Undergoing Percutaneous Coronary Intervention
Chest,
January 1, 2001;
119
(2009):
321S - 336S.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Manhapra and S. Borzak
Regular review: Treatment possibilities for unstable angina
BMJ,
November 18, 2000;
321(7271):
1269 - 1275.
[Full Text]
|
|
|
|
|
|
|
D. L. Bhatt and E. J. Topol
Current Role of Platelet Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes
JAMA,
September 27, 2000;
284(12):
1549 - 1558.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Singh, C. S. Rihal, P. B. Berger, M. R. Bell, D. E. Grill, K. N. Garratt, G. W. Barseness, and D. R. Holmes Jr.
Improving outcome over time of percutaneous coronary interventions in unstable angina
J. Am. Coll. Cardiol.,
September 1, 2000;
36(3):
674 - 678.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Braunwald, E. M. Antman, J. W. Beasley, R. M. Califf, M. D. Cheitlin, J. S. Hochman, R. H. Jones, D. Kereiakes, J. Kupersmith, T. N. Levin, et al.
ACC/AHA guidelines for the management of patients with unstable angina and non-st-segment elevation myocardial infarction: A report of the american college of cardiology/ american heart association task force on practice guidelines (committee on the management of patients with unstable angina)
J. Am. Coll. Cardiol.,
September 1, 2000;
36(3):
970 - 1062.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M.E Bertrand, M.L Simoons, K.A.A Fox, L.C Wallentin, C.W Hamm, E McFadden, P.J de Feyter, G Specchia, and W Ruzyllo
Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation. Recommendations of the Task Force of the European Society of Cardiology: Recommendations of the Task Force of the European Society of Cardiology
Eur. Heart J.,
September 1, 2000;
21(17):
1406 - 1432.
[PDF]
|
|
|
|
|
|
|
M. Cusack, S. Redwood, and J. Coltart
Recent advances in ischaemic heart disease
Postgrad. Med. J.,
September 1, 2000;
76(899):
542 - 546.
[Full Text]
|
|
|
|
|
|
|
A.M. Lincoff and E.J. Topol
Platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary revascularization: what more needs to be proven?
Eur. Heart J.,
June 1, 2000;
21(11):
863 - 867.
[PDF]
|
|
|
|
|
|
|
A. M. Lincoff, R. M. Califf, and E. J. Topol
Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease
J. Am. Coll. Cardiol.,
April 1, 2000;
35(5):
1103 - 1115.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Al Suwaidi, P. B. Berger, C. S. Rihal, K. N. Garratt, M. R. Bell, H. H. Ting, J. F. Bresnahan, D. E. Grill, and D. R. Holmes Jr.
Immediate and long-term outcome of intracoronary stent implantation for true bifurcation lesions
J. Am. Coll. Cardiol.,
March 15, 2000;
35(4):
929 - 936.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. S. Kleiman, A. M. Lincoff, G. C. Flaker, K. S. Pieper, R. G. Wilcox, L. G. Berdan, T. J. Lorenz, D. V. Cokkinos, M. L. Simoons, E. Boersma, et al.
Early Percutaneous Coronary Intervention, Platelet Inhibition With Eptifibatide, and Clinical Outcomes in Patients With Acute Coronary Syndromes
Circulation,
February 22, 2000;
101(7):
751 - 757.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Mehran, G. Dangas, G. S. Mintz, A. J. Lansky, A. D. Pichard, L. F. Satler, K. M. Kent, G. W. Stone, and M. B. Leon
Atherosclerotic Plaque Burden and CK-MB Enzyme Elevation After Coronary Interventions : Intravascular Ultrasound Study of 2256 Patients
Circulation,
February 15, 2000;
101(6):
604 - 610.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Ambrose and G. Dangas
Unstable Angina: Current Concepts of Pathogenesis and Treatment
Arch Intern Med,
January 10, 2000;
160(1):
25 - 37.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Kaushansky
Blood: New designs for a new millennium
Blood,
January 1, 2000;
95(1):
1 - 6.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Brodison, R. S More, and A. Chauhan
Stents in medicine: The role of coronary angioplasty and stenting in acute myocardial infarction
Postgrad. Med. J.,
October 1, 1999;
75(888):
591 - 598.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
C. E. Chambers, S. T Riebel, and M. Kozak
Interventional Cardiology: Advances in Percutaneous Techniques for the Treatment of Cardiac Disease
Seminars in Cardiothoracic and Vascular Anesthesia,
July 1, 1999;
3(2):
109 - 125.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. D. Tselepis, J. A. Goudevenos, A. P. Tambaki, L. Michalis, C. S. Stroumbis, D. C. Tsoukatos, M. Elisaf, and D. A. Sideris
Platelet aggregatory response to platelet activating factor (PAF), ex vivo, and PAF-acetylhydrolase activity in patients with unstable angina: effect of c7E3 Fab (abciximab) therapy
Cardiovasc Res,
July 1, 1999;
43(1):
183 - 191.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Vorchheimer, J. J. Badimon, and V. Fuster
Platelet Glycoprotein IIb/IIIa Receptor Antagonists in Cardiovascular Disease
JAMA,
April 21, 1999;
281(15):
1407 - 1414.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. E. Lempert, A. M. Malek, V. V. Halbach, C. C. Phatouros, C. F. Dowd, and R. T. Higashida
Rescue Treatment of Acute Parent Vessel Thrombosis With Glycoprotein IIb/IIIa Inhibitor During GDC Coil Embolization
Stroke,
March 1, 1999;
30
(3):
693 - 695.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. R. Azar, R. G. McKay, P. D. Thompson, J. A. Hirst, J. F. Mitchell, D. B. Fram, D. D. Waters, and F. J. Kiernan
Abciximab in primary coronary angioplasty for acute myocardial infarction improves short- and medium-term outcomes
J. Am. Coll. Cardiol.,
December 1, 1998;
32(7):
1996 - 2002.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Halon, M. Y. Flugelman, A. Merdler, H. Rennert, J. Shahla, and B. S. Lewis
Long-term (10-year) outcome in patients with unstable angina pectoris treated by coronary balloon angioplasty
J. Am. Coll. Cardiol.,
November 15, 1998;
32(6):
1603 - 1609.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. E. Bedell, T. B. Graboys, S. Ravid, R. C. Thompson, M. T. Roe, T. E. Bowen, E. J. Topol, J. M. Huitink, J. J. Bax, W. E. Boden, et al.
Management of Non-Q-Wave Myocardial Infarction
N. Engl. J. Med.,
November 5, 1998;
339(19):
1395 - 1398.
[Full Text]
|
|
|
|
|
|
|
D. R. Holmes Jr., J. Hirshfeld Jr., D. Faxon, R. Vlietstra, A. Jacobs, S. B. King III, T. M. Bashore, N. D. Bridges, C. B. Higgins, L. F. Hiratzka, et al.
ACC expert consensus document on coronary artery stents: Document of the American College of Cardiology
J. Am. Coll. Cardiol.,
November 1, 1998;
32(5):
1471 - 1482.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. M. M. van Beusekom, D. M. Whelan, S. H. Hofma, S. C. Krabbendam, V. W. M. van Hinsbergh, P. D. Verdouw, and W. J. van der Giessen
Long-term endothelial dysfunction is more pronounced after stenting than after balloon angioplasty in porcine coronary arteries
J. Am. Coll. Cardiol.,
October 1, 1998;
32(4):
1109 - 1117.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
The PURSUIT Trial Investigators
Inhibition of Platelet Glycoprotein IIb/IIIa with Eptifibatide in Patients with Acute Coronary Syndromes
N. Engl. J. Med.,
August 13, 1998;
339(7):
436 - 443.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Fuster, J. J. Badimon, and J. H Chesebro
Atherothrombosis: mechanisms and clinical therapeutic approaches
Vascular Medicine,
August 1, 1998;
3(3):
231 - 239.
[Abstract]
[PDF]
|
|
|
|
|
|
|
International, Randomized, Controlled Trial of Lamifiban (a Platelet Glycoprotein IIb/IIIa Inhibitor), Heparin, or Both in Unstable Angina
Circulation,
June 23, 1998;
97(24):
2386 - 2395.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
